Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize, and Treat the mpMRI Invisible Lesion
- 1 December 2024
- book chapter
- Published by Springer Nature
- p. 219-240
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate CancerJAMA Oncology, 2021
- Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancerAbdominal Radiology, 2018
- A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial BiopsyJAMA Oncology, 2016
- Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF RecommendationsJAMA Internal Medicine, 2016
- Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsiesCancer, 2016
- Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsiesWorld Journal of Urology, 2015
- The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐eraInternational Journal of Cancer, 2014
- Clinical‐Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three‐Dimensional Reconstruction of Prostatectomy SpecimensThe Prostate, 2012
- Laterally directed biopsies detect more clinically threatening prostate cancer: Computer simulated resultsThe Prostate, 2003
- Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancerCancer, 1993